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Introduction: Traditional scientific review processes are not well suited for evaluating the 
merits of research in situations where the available scientific evidence is limited and if review 
panels have widely divergent opinions. This study tested whether a Delphi process is useful 
in grant selection.
Materials and method: A Delphi process prioritized novel research proposals in pancreatic 
cancer. Five reviewers holding similar grants overseas ranked research applications by scientific 
merit, innovativeness, and level of risk.
Result: Three rounds of voting evaluated the best 10 applications received. In the first 
round of the Delphi process, scores ranged from 5.0 to 8.3. After the second round, the 
cumulative scores of the eight remaining applications ranged from 10 to 12.6. At the end of 
the third round, the final cumulative scores of the remaining six applications ranged from 
13.6 to 18.2. The four highest ranking applications were recommended for funding, with 
agreement from reviewers.
Conclusion: A modified Delphi process proved to be an efficient, transparent, and equitable 
method of reviewing novel grant applications in a specialized field of research, where no local 
expertise was available. This process may also be useful for other peer review processes, par-
ticularly where there is limited access to local experts.
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Introduction
The scientific review process traditionally involves a group decision-making method, 
where evaluations are mediated and advocated by spokespersons, and a judgment of 
quality and merit is made by the group through several prespecified steps. A group 
decision-making process has many advantages, ie, access to a large pool of expertise, 
member interaction can be a catalyst for debate resulting in new insights into a   problem, 
group interactions can filter out individual idiosyncrasies, and a group decision may 
carry more weight than an individual one.1
Nevertheless, committee decision-making can also have disadvantages. There is 
often a tendency for conformity, because group members may feel pressure (real or 
imagined) to agree with other panel members,1 and committee processes may be con-
trolled by more dominant personalities. Members may be unwilling to take a position 
before all facts are known, or they may be reluctant to change their view once they 
have stated it publicly. In addition, members may avoid publicly contradicting senior 
members of the panel and concerns about losing face may preclude members from 
taking a public stance in a matter where results are uncertain.2International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
226
Holliday and Robotin
Given the variety of opinions that may exist when a 
diverse group considers a highly technical and polarizing 
topic, approaches to reach consensus (the Delphi method, 
the nominal group process, and the consensus development 
conference) are increasingly used to make complex decisions 
in medicine and health.3 Consensus methods perform well 
in situations where the evidence is limited, unclear, or when 
results diverge widely, where they can provide a link between 
clinical reasoning and clinical research.4
The Delphi method is a way of collating and organising 
feedback provided by a group of experts. Modifications of 
the Delphi technique have been used for developing clini-
cal guidelines and quality indicators,5–10 developing clinical 
decision aids,11 identifying research priorities,12–17 defining 
priorities in cancer care,18 and identifying health practitio-
ners’ educational priorities.19
This study aimed to ascertain whether the Delphi process 
can be an efficient and transparent grant assessment method 
and whether it can make a significant contribution to the peer 
review process. If the process is acceptable to stakeholders, 
who view it as being both fair and reproducible, it may be 
considered as adjunct or an alternative to a grant selection 
process.
Materials and methods
A research procurement method was developed by the Cancer 
Council New South Wales (CCNSW), to address an ambi-
tious set of research priorities identified through the New 
South Wales Pancreatic Cancer Network Strategic Research 
Partnership grant. Details about the research prioritization 
process with experts in the field, including consumers, have 
recently been published in the peer reviewed literature.20 
Innovator grants in pancreatic cancer aim to support innova-
tive research of high quality and potential, but unlikely to 
be considered by traditional funding bodies (due to unusual 
research questions or design, and the investigators having 
a limited research track record or a lack of experience in 
pancreatic cancer research).
Given the specific aims of these grants, it was accepted 
that they may involve a higher than usual risk of failure, but 
the CCNSW was willing to consider research proposals that 
demonstrated high merit and feasibility upon peer review, as 
potential “high risk-high return” propositions. The mitigation 
of these risks was through the restricted term of funding, 
offered for one year at AUD 100,000 per grant.
A round of funding for innovator grants in pancreatic 
cancer was announced by the CCNSW in early 2008. 
Based on the average number of pancreatic cancer research 
  applications submitted through the traditional National 
Health and Medical Research Council (NHMRC) funding 
scheme and taking into account the level of local activity 
in pancreatic cancer research, the CCNSW expected fewer 
than five innovator grant applications to be submitted. How-
ever, 19 applications were received from research groups 
throughout Australia.
This presented a number of challenges for the CCNSW. 
The original aim was to process all applications within four 
weeks of receipt, through a peer review process involving at 
least two independent experts. With a relatively large volume 
of applications to review from institutions nationwide, and 
because most experts in the field were listed investigators 
in these applications (or had conflicts of interest to declare), 
it was agreed that the traditional review process, ie, inviting 
local experts as grant application reviewers, was no longer 
applicable. Therefore, an alternative review process was 
developed.
Firstly, a convened independent scientific panel reviewed 
all applications against the specified eligibility criteria and 
agreed on those proposals meeting the stated objectives of the 
funding scheme. These applications were recommended for 
peer review. It was proposed that the peer review process be 
conducted online, using a modified Delphi process to reach 
consensus among a convened expert group.
The innovator grant Delphi process
The modified Delphi was held over three rounds on 15–31 
March 2009, and involved five experts holding grants with 
the Pancreatic Cancer Action Network in the US. The three 
rounds examined the scientific merit, innovativeness, and 
level of risk of each application (see Figure 1). Participants 
were required to declare any conflicts of interest before the 
review. At the end of each round, the two lowest ranking 
applications were eliminated, leaving four applications to be 
recommended for funding at the end of the process.
In Round 1, reviewers were provided with the 10 applica-
tions and a scoring sheet. In an attempt to reduce the admin-
istrative burden for applicants and reviewers, all applications 
were limited to six pages. Reviewers were invited to rate 
the scientific merit of each research proposal for clarity and 
measurability of the endpoint of the research, the scientific 
quality of the grant proposal, its originality, the adequacy of 
the study design to achieve the research goals, and whether 
the potential impact of the study would warrant its funding.
The scoring sheets were returned to the CCNSW for 
collation and analysis. The scores used for each category 
of answers were “yes” = 2 points, “no” = 0 points, and 
“unsure” = 1 point. Delphi participants were provided with 
a   de-identified summary table, documenting the scores International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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assigned to each application by each reviewer, as well as the 
overall mean score for each application. The scores were 
listed in decreasing order of magnitude and it was proposed 
that the two lowest scoring proposals be eliminated from the 
subsequent round.
At this point, the panel was invited to review the overall 
ranking, provide feedback on the process, and advise if they 
wished to proceed to the next round, or if they had objec-
tions, to advise the CCNSW of their nature and if a recount 
was required.
In Round 2, participants were asked to rank the remaining 
applications for their innovative potential. Participants were 
invited to assess the degree of innovativeness of each of the 
eight research applications on a Likert scale from 1 (“not at 
all original”), to 6 (“very innovative”).
The results were sent to the CCNSW and collated. 
A table documenting the individual innovativeness scores, 
the mean innovativeness score for each application, and the 
mean scientific merit score from Round 1 was circulated to 
the group. The sum of both mean scores was calculated and 
the applications were again ranked from the highest to the 
lowest, based upon the total score.
The group was then asked to comment on the results, and 
the lowest two ranking applications were eliminated from 
the final round. Participants were again asked if they had any 
objections before proceeding to the next round.
In Round 3, participants were asked to rank the remaining 
six proposals according to their degree of risk, vis-à-vis their 
potential contribution to pancreatic cancer research, where 
the highest score (6) was awarded for low risk-high return 
applications and the lowest score (1) was awarded for high 
risk-low return and low risk-low return applications. High 
risk-high return propositions were awarded a score of 4.
As in previous rounds, a table was circulated, listing 
scores assigned to each application in relation to level of risk 
and the mean level of risk score. The mean and cumulative 
total scores of the scientific score, innovativeness score, and 
level of risk score were calculated and forwarded to partici-
pants. Applications were listed from the highest ranking to the 
lowest ranking based on this cumulative score. The overall 
score was circulated to the expert assessors who were able 
to see the rank of each proposal.
At the completion of the Delphi process, feedback was 
sought from reviewers on the process, its usefulness, and 
possible alternatives or modifications, to increase its validity 
and relevance as a grant discriminator tool.
Results
In Round 1 (n = 5 participants, 100% response rate), applica-
tions were scored against the five agreed criteria related to 
scientific merit. Mean application scores across all criteria 
ranged from 8.3 to 5.0. The two lowest ranking applications 
(scoring a mean of 5.8 and 5.0, respectively) were eliminated 
from the subsequent round, leaving eight applications to 
progress to Round 2. None of the reviewers recorded any 
objections at the end of Round 1.
Cumulative Round 2 (or innovativeness) scores ranged 
from 10.0 to 12.6, with the lowest two applications scoring 
Scientific merit score
Innovativeness score
 Six applications
Ranking
 10 applications
Eight  applications
Scientific merit score
Innovativeness score
Ranking Lowest ranking
two eliminated 
Level of risk score 
Scientific merit score
Innovativeness score
Level of risk score
Ranking Lowest ranking
two eliminated
Final four applications Recommended for funding
Lowest ranking  
two eliminated 
Figure 1 Diagrammatic representation of the Delphi grant process.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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10.4 and 10.0, respectively. No objections were recorded at 
the end of Round 2, and the two lowest scoring applications 
were eliminated, leaving six applications in Round 3.
In Round 3, scoring for the degree of risk associated with 
funding the research, cumulative mean scores ranged from 
13.6 to 18.2. The lowest two applications, scoring a mean of 
14.6 and 13.6, were eliminated. The remaining four applica-
tions represented the priority list recommended by the expert 
group for funding.
All rounds were scored by all five experts, for a 100% 
response rate throughout the process.
The widest range of scores range was observed in 
Round 1, which ranked scientific merit. There was some 
movement in relation to where applications ranked before 
and after scores were cumulated in rounds 2 and 3, however, 
this did not affect overall ranking in the final round assessing 
risk level (see Table 1).
Following the process, participants (n = 4, 80% response 
rate) were asked a series of questions to evaluate their experi-
ence with the Delphi process (see Table 2). Responses were 
positive overall and the feedback provided suggested that 
the Delphi process was a fair way of assessing the merit of 
the applications, which was well suited for small application 
pools, and offering unique solutions, compared with other 
review processes. The reviewers suggested that incorporat-
ing some free discussion among the panel between rounds 
would be useful.
Discussion
Here we have described a process that can assist the assess-
ment and ranking of research grant applications, using a 
modified Delphi technique. To our knowledge, this process 
represents the first use of a Delphi process to appraise and 
rank research applications. Its ease of administration, repro-
ducibility, and accessibility makes this a useful adjunct to the 
traditional processes of grant selection, or as a stand-alone 
process for reviewing very specialized types of research 
applications, where innovativeness and risk-taking are 
rewarded, in conjunction with scientific merit.
This method offered the advantages of expediency and 
speed, as the Delphi process can be carried out electronically 
and outcomes collated promptly, in preparation for the next 
step. We believe that its greatest contribution would be in 
evaluating grant applications in highly specialized research 
areas, where the availability of local reviewers is very lim-
ited, or where the contribution of a diverse, interstate, or 
international panel of experts would be a great asset to the 
proceedings.
Many research organizations tailor review processes 
according to the nature or aim of the grant or of the procure-
ment strategy, eg, attracting researchers who have a sound 
or very novel idea but may lack a well-established track 
record in particular areas of research. The process adequately 
addressed the funder’s specific aims and the specific require-
ments of reviewing novel grant applications which have a 
higher level of risk than what is acceptable through traditional 
grant schemes.
In 2008, the National Institute of Health (NIH) acknowl-
edged that a specialized review process was required to assess 
grant applications equitably from first-time applicants.21 
Modeled on similar programs in Europe and Japan, it was 
proposed that where a researcher was applying to the NIH for 
the first time, these applications would be reviewed against 
each other, rather than against all applications, which include 
those from experienced researchers. In this same review, the 
NIH acknowledged issues around the length of applications, 
identifying appropriate reviewers, and allowing some flex-
ibility for reviewers to reduce the burden on their time.
While the NIH program may represent a different grant 
process, many of the same issues are germane to Australian 
Table 1 Mean scores (range) and ranks for applications after each round of the Delphi process
Application 
unique identifier
Post-round 1 Post-round 2 Post-round 3
Mean score 
scientific merit 
Rank Mean score 
innovativeness 
Cumulative 
score
Rank Mean score 
level or risk
Cumulative 
score
Rank 
Applicant 1 8.3 1 3.5 11.8 2 3.8 15.6 3
Applicant 2 8.0 2 4.6 12.6 1 5.6 18.2 1
Applicant 3 7.8 3 3.8 11.6 4 3.0 14.6 5
Applicant 4 7.4 4 4.0 11.4 5 3.8 15.2 4
Applicant 5 6.8 5 4.0 10.8 6 2.8 13.6 6
Applicant 6 6.8 5 3.2 10.0 8 – – –
Applicant 7 6.8 5 4.8 11.6 3 4.4 16.0 2
Applicant 8 6.2 8 4.2 10.4 7 – – –
Applicant 9 5.8 9 – – – – – –
Applicant 10 5.0 10 – – – – – –International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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pancreatic cancer research and were addressed here through 
the innovator grant review process. For example, innovator 
grant applications could not exceed six pages in length, in 
order to reduce the administrative and time burden on both 
applicants and reviewers. While this was initially developed 
to decrease the time in which applications were prepared 
and reviewed, it was equally important to the success of this 
Delphi process, because lengthy applications would have 
made the review process very onerous for the expert panel. 
Further investigation is needed to measure the time and effort 
required by assessors, but this should be relative to the level 
of risk and funding of the grants being offered.
The process successfully addressed the issue of finding 
appropriate reviewers, because in this case it was necessary 
to search for international reviewers in order to avoid con-
flicts of interest. Our online review process was less costly, 
quicker, and more flexible with regard to reviewer time 
commitment, because the process could accommodate their 
individual schedules.
Nevertheless, the comments received from reviewers 
about the process highlight a clear limitation of the Delphi 
technique in reviewing grant applications, particularly in 
relation to the need for some discussion between rounds. 
For example, where there is a large difference in the range 
of scores, a discussion between voting rounds could be 
beneficial. This could, however, introduce the shortcomings 
of a committee decision-making process, particularly panel 
members’ tendency for conformity, or the risk that the pro-
cess would be controlled by more dominant personalities.1 
This may be ultimately counterproductive compared with the 
Delphi process, where individual responses are deidentified 
and collated in order to facilitate the reaching of consensus. 
However, circulating comments, without discussion, may be 
beneficial in the future and would reduce the risk of confor-
mity while maintaining the flexibility of the Delphi.
The indicators used in our Delphi process differ from those 
used in traditional grant schemes, such as those administered in 
Australia by the NHMRC, as the latter emphasize an established 
track record in research and budgetary considerations when 
ranking applications. The indicators used in the Delphi pro-
cess were scientific merit, innovativeness, and level of risk.
Traditional funding schemes require an in-depth scrutiny 
of proposed budgets, due to the larger funding amounts made 
available to research teams. While this was not an issue in our 
situation, because the relatively small amount of funds awarded 
(AUD 100,000 per grant) was simply “start-up grant money”, 
encouraging innovativeness and lateral thinking, a closer 
review of larger budgets is required than what can be possible 
through a Delphi process alone, so further research into the 
merit of the Delphi process as an adjunct to the traditional 
Table 2 Reviewer feedback
Would more discussion between rounds 
be beneficial and, if so, would it have 
altered your final decision?
Discussion would have been beneficial, especially on grants where there was a clear difference in opinion, 
ie, some reviewers scored it highly and others poorly.
Discussions or written comments would be beneficial. Whether it would alter the outcome is hard to say.
Ideally, one conference call would be ideal – however given the time differences I think the current 
system works fine.
I thought the review process went well, however, I do feel that having a conference call at some point 
would help. Many applications are similar in nature/merit and discussing which one to place higher than 
the other at some point of the process would have been desirable.
Did cumulative scoring result in the 
optimum outcome?
The multiple rounds were kind of a waste of time since the leaders did not move very much between 
each round.
It really depends on what is weighted more in each round. The round weighing scientific merit was 
omitted. That resulted in grants emphasizing novelty over scientific merit.
Yes.
How did this process compare with 
more traditional scientific peer reviews 
and grant assessment processes?
It was actually more time-consuming as I had to go back and read the grants in between rounds to 
remember and rank them again. I think we could have answered all of the questions at the first round, 
discussed it quickly, and then made the decision.
This is very similar to the mechanism where novelty is emphasized. This is very common for foundation 
grants or non-renewable grants. The cumulative scoring is novel to me. I think it works fairly well. each 
round does its intended purpose of weeding out certain proposals.
Probably easier.
Would you recommend this process in 
the future to other funding schemes?
Maybe. It really helps to be able to review the ranking of the grant in each round. This feature is very 
different from study sections that I have served on, where each grant is evaluated independent from other 
applications and no ranking is given. I would recommend ranking for all small pools of applications. 
Yes, I think it is fair.
I think overall the experience was very positive. I think whether to alter the process really depends on 
what kind of results is expected. I think the current process definitely weighs novelty over scientific merit. 
If that’s what the Foundation wants, the result is pretty close to the aim.International Journal of General Medicine
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grant selection process may be advantageous, as would a trial 
of the Delphi process with other novel grant schemes.
Conclusion
The value of the Delphi process for grant reviews therefore 
appears to lie primarily with novel grant schemes, particu-
larly where the aim is to increase researcher involvement in 
understudied or relatively new research fields. The process 
is well suited if the stated goal is to attract new researchers 
into the field, regardless of their track record, who may look 
for different, nonconventional solutions to research ques-
tions, and/or may wish to move into a new research field. 
In our experience, a modified Delphi process proved an 
efficient and equitable method of grant review in a research 
area with a high potential for conflicts of interest, and we 
contend that it has a wider applicability in other research 
grant evaluations.
This process may also be useful in other peer review 
processes, including ethics committee deliberations, progress 
evaluations of research grant applications, and guideline 
development, particularly where there is a limited availability 
of local expert reviewers.
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